Quince Therapeutics Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026

Reuters09-12

Quince <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026

Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced it will host a virtual Investor Day on October 2, 2025. The event will include presentations on the company's Autologous Intracellular Drug Encapsulation (AIDE) technology and its potential applications in treating rare diseases. A key highlight will be the discussion on the proprietary eDSP System, a drug/device combination designed for chronic corticosteroid administration without toxicity. The company will provide insights into its lead indication, Ataxia-Telangiectasia (A-T), and the ongoing pivotal Phase 3 NEAT clinical trial, with topline results anticipated in the first quarter of 2026. The event will also cover Quince's regulatory strategies and commercial development plans, including its collaboration with Option Care Health. Results from the NEAT study have not yet been presented, as they are expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911197139) on September 11, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566591956?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566591956","market":"us","top_or_hot":-1,"title":"Quince Therapeutics Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced it will host a virtual Investor Day on October 2, 2025. The event will include presentations on the company's Autologous Intracellular Drug Encapsulation (AIDE) technology and its potential applications in treating rare diseases. A key highlight will be the discussion on the proprietary eDSP System, a drug/device combination designed for chronic corticosteroid administration without toxicity. The company will provide insights into its lead indication, Ataxia-Telangiectasia (A-T), and the ongoing pivotal Phase 3 NEAT clinical trial, with topline results anticipated in the first quarter of 2026. The event will also cover Quince's regulatory strategies and commercial development plans, including its collaboration with <a href=\"https://laohu8.com/S/OPCH\">Option Care Health</a>. Results from the NEAT study have not yet been presented, as they are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911197139) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quince Therapeutics Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuince Therapeutics Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-12 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced it will host a virtual Investor Day on October 2, 2025. The event will include presentations on the company's Autologous Intracellular Drug Encapsulation (AIDE) technology and its potential applications in treating rare diseases. A key highlight will be the discussion on the proprietary eDSP System, a drug/device combination designed for chronic corticosteroid administration without toxicity. The company will provide insights into its lead indication, Ataxia-Telangiectasia (A-T), and the ongoing pivotal Phase 3 NEAT clinical trial, with topline results anticipated in the first quarter of 2026. The event will also cover Quince's regulatory strategies and commercial development plans, including its collaboration with <a href=\"https://laohu8.com/S/OPCH\">Option Care Health</a>. Results from the NEAT study have not yet been presented, as they are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911197139) on September 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OPCH","symbol_name":"Option Care Health Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250911:nNDL7RWpN1:1","article_id":"2566591956","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566591956","pubTimestamp":1757621136,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced it will host a virtual Investor Day on October 2, 2025. The event will include presentations on the company's Autologous Intracellular Drug Encapsulation  technology and its potential applications in treating rare diseases. A key highlight will be the discussion on the proprietary eDSP System, a drug/device combination designed for chronic corticosteroid administration without toxicity. The company will provide insights into its lead indication, Ataxia-Telangiectasia (A-T), and the ongoing pivotal Phase 3 NEAT clinical trial, with topline results anticipated in the first quarter of 2026. The event will also cover Quince's regulatory strategies and commercial development plans, including its collaboration with Option Care Health. Results from the NEAT study have not yet been presented, as they are expected in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OPCH":"Option Care Health Inc","QNCX":"Quince Therapeutics, Inc.","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4139":"生物科技","BK4196":"保健护理服务"},"translate_title":"Quince Therapeutics宣布针对共济失调-毛细血管扩张症的关键3期NEAT试验，预计将于2026年第一季度取得主要结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPCH":0.9,"QNCX":0.9},"content_text":"Quince Therapeutics Announces Pivotal Phase 3 NEAT Trial for Ataxia-Telangiectasia with Topline Results Expected in Q1 2026\n    \n\n        Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced it will host a virtual Investor Day on October 2, 2025. The event will include presentations on the company's Autologous Intracellular Drug Encapsulation (AIDE) technology and its potential applications in treating rare diseases. A key highlight will be the discussion on the proprietary eDSP System, a drug/device combination designed for chronic corticosteroid administration without toxicity. The company will provide insights into its lead indication, Ataxia-Telangiectasia (A-T), and the ongoing pivotal Phase 3 NEAT clinical trial, with topline results anticipated in the first quarter of 2026. The event will also cover Quince's regulatory strategies and commercial development plans, including its collaboration with Option Care Health. Results from the NEAT study have not yet been presented, as they are expected in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250911197139) on September 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566591956","isCrawlerRequest":true}